iMDx Q2 Loss Deepens, Cash Runway Tightens; FDA Dialogue Continues
IMDX has more than doubled off its 52-week low of $2.33 on light trading volume (0.3× avg).
Summary
iMDx's Q2 loss widened to $11.3M on only $239K in revenue. Cash is $17.8M and the company flagged going concern risks, though management expects to have sufficient liquidity for the next year. FDA review of its lead transplant test continues.
Key Events · Earnings and Guidance · IMDX
-
Q2 Loss Widens
The net loss deepened to $11.3M from $9.7M a year ago, on revenue of just $239K. Operating cash burn hit $16.9M in H1 2026.
-
Cash Runway Under Pressure
Cash and equivalents fell to $17.8M from $25.8M at year-end 2025. Despite raising $24.6M net in February 2026, the company is burning cash rapidly.
-
Going Concern Risk Flagged
Management's evaluation raised substantial doubt about the company's ability to continue as a going concern, though it believes cost-cutting and potential future financings will provide sufficient liquidity for at least 12 months.
-
FDA Review Ongoing
The FDA is still reviewing the GraftAssureDx submission made in March 2026. No approval timeline was provided, but the company described dialogue as 'meaningful and productive.'
Analysis · IMDX · Life Sciences
Insight Molecular Diagnostics posted a wider Q2 net loss of $11.3 million on just $239,000 in revenue, with operating cash burn reaching $16.9 million in the first half. Cash stands at $17.8 million, and the company's own going concern evaluation acknowledges substantial doubt about its ability to continue, though management believes its cost-cutting and financing plans will bridge the next twelve months. The FDA is still reviewing the GraftAssureDx submission, with no approval timeline given. A recent Medicare LCD expansion is a tailwind, but the immediate focus is on whether the company can fund operations long enough to reach commercialization.
How filings like this one have moved
In the 30 days to Oct 4, 2026, 36.7% of the 1015 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMDX was trading at $4.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $154M. The 52-week trading range was $2.33 to $8.51. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.